What is the time it takes to realize results
What is a GLP-1-friendly diet
The key milestones include: exenatide approval (2005), liraglutide approval (2010), semaglutide injection approval (2017), oral semaglutide with SNAC approval (2019), orforglipron cryo-EM structure published (2020), orforglipron Phase 2 results in NEJM (2023), orforglipron Phase 3 ATTAIN-1 results in NEJM (2025), and FDA regulatory submission (2025)
Research has explored its role in helping to improving energy, increased metabolism, cognitive performance, brain fog, and exercise recovery
As employers grapple with how to pay for these medications, some are exploring strategies like: Limiting coverage to patients with the highest need Pairing GLP-1 coverage with a dietician to improve nutrition, support for physical exercise and intensive behavioral health therapy Alternative payment models that hold drug manufacturers accountable for producing results GLP-1s deliver impressive clinical results but at a steep cost